• Earlier this week, Artisan Partners disclosed that it had initiated a new position in IQVIA Holdings, citing the company’s mix of clinical research services, recurring data and analytics revenue, and technology solutions as key attractions.
• The investor’s emphasis on IQVIA’s potential to harness AI while managing sector demand softness highlights how its data-rich, recurring-revenue model may offer an edge in a changing clinical research landscape.
• Next, we’ll examine how Artisan Partners’ focus on IQVIA’s AI exposure and recurring analytics revenue could influence the company’s broader investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

IQVIA Holdings Investment Narrative Recap

To own IQVIA, you need to be comfortable with a business that mixes cyclical clinical research projects with recurring data and analytics revenue, while leaning into AI to stay relevant. Artisan Partners’ new position underlines that thesis but does not materially change the near term picture, where the key catalyst remains IQVIA’s AI rollout and the biggest risk is pricing and margin pressure in a competitive CRO market.

Among recent announcements, the launch of IQVIA.ai with NVIDIA stands out as most relevant to Artisan’s AI-focused thesis. IQVIA is positioning this agentic AI platform across clinical, commercial, and real world data workflows, which ties directly into the idea that its data rich, recurring revenue businesses could benefit if AI tools help improve efficiency and make its services stickier with clients.

Yet, beneath the AI promise, tighter pricing and high leverage remain risks that investors should be aware of, especially if...

IQVIA Holdings' narrative projects $19.7 billion revenue and $2.0 billion earnings by 2029. This requires 5.8% yearly revenue growth and a $0.6 billion earnings increase from $1.4 billion today.

Uncover how IQVIA Holdings' forecasts yield a $226.95 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts take a much harsher view than Artisan, assuming revenue of about US$19.5 billion and earnings near US$1.8 billion by 2029, so you should recognize how differently others weigh AI opportunity against data privacy and client insourcing risk before deciding which narrative you find more convincing.

Explore 3 other fair value estimates on IQVIA Holdings - why the stock might be worth just $226.95!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your IQVIA Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free IQVIA Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IQVIA Holdings' overall financial health at a glance.

Looking For Alternative Opportunities?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.